全文获取类型
收费全文 | 89799篇 |
免费 | 3977篇 |
国内免费 | 1259篇 |
专业分类
耳鼻咽喉 | 523篇 |
儿科学 | 1400篇 |
妇产科学 | 975篇 |
基础医学 | 11111篇 |
口腔科学 | 3827篇 |
临床医学 | 7104篇 |
内科学 | 17960篇 |
皮肤病学 | 1849篇 |
神经病学 | 6230篇 |
特种医学 | 2443篇 |
外国民族医学 | 5篇 |
外科学 | 14204篇 |
综合类 | 6089篇 |
现状与发展 | 3篇 |
一般理论 | 5篇 |
预防医学 | 7218篇 |
眼科学 | 1667篇 |
药学 | 5911篇 |
20篇 | |
中国医学 | 2996篇 |
肿瘤学 | 3495篇 |
出版年
2023年 | 1251篇 |
2022年 | 2162篇 |
2021年 | 3592篇 |
2020年 | 2503篇 |
2019年 | 6488篇 |
2018年 | 6628篇 |
2017年 | 4222篇 |
2016年 | 1555篇 |
2015年 | 1530篇 |
2014年 | 3097篇 |
2013年 | 3082篇 |
2012年 | 2227篇 |
2011年 | 2636篇 |
2010年 | 2232篇 |
2009年 | 1899篇 |
2008年 | 2070篇 |
2007年 | 2002篇 |
2006年 | 1751篇 |
2005年 | 1533篇 |
2004年 | 1311篇 |
2003年 | 1355篇 |
2002年 | 998篇 |
2001年 | 975篇 |
2000年 | 839篇 |
1999年 | 781篇 |
1998年 | 621篇 |
1997年 | 638篇 |
1996年 | 533篇 |
1995年 | 520篇 |
1994年 | 477篇 |
1993年 | 412篇 |
1992年 | 376篇 |
1991年 | 332篇 |
1990年 | 280篇 |
1989年 | 258篇 |
1988年 | 241篇 |
1987年 | 201篇 |
1985年 | 3019篇 |
1984年 | 3538篇 |
1983年 | 2959篇 |
1982年 | 3449篇 |
1981年 | 3134篇 |
1980年 | 2592篇 |
1979年 | 2559篇 |
1978年 | 2091篇 |
1977年 | 1574篇 |
1976年 | 2021篇 |
1975年 | 1524篇 |
1974年 | 1330篇 |
1973年 | 1279篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
52.
53.
54.
A. Montalto V. Piazza F. Albi R. Gherli C. Contento A. Palermo F. Musumeci 《Transplantation proceedings》2019,51(1):206-209
Background
Pump speed optimization in patients implanted with a ventricular assist device represents a major challenge during the follow-up period. We present our findings on whether combined invasive hemodynamic ramp tests and cardiopulmonary exercise testing (CPX) can help optimize patient management.Methods
Eighteen patients implanted with a HeartMate 3 (HM3) device underwent ramp tests with right heart catheterization (including central venous pressure [CVP], pulmonary artery pressure, pulmonary capillary wedge pressure [PCWP], and blood pressure) and echocardiography. Data were recorded at up to 4 speed settings. Speed changes were in steps of 200 revolutions/min (rpm). Evaluation of functional capacity by CPX was conducted according to the modified Bruce protocol.Results
Only 30% of patients had normal PCWPs at their original rpm settings. In going from lowest to highest speeds, cardiac output improved by 0.25 ± 0.35 L/min/step (total change, 1.28 ± 0.3 L/min), and PCWP decreased by 1.9 ± 0.73 mm Hg/step (total change, 6 ± 1.6 mm Hg). CVP and systolic blood pressure did not change significantly with rpm. The rpm assessment was adjusted based on test results to achieve CVPs and PCWPs as close to normal limits as possible, which was feasible in all patients. On CPX, all patients demonstrated good performance (peak VO2, 16.8 ± 3.5 mL/kg/min).Conclusion
Hemodynamic ramp testing provides an objective means of optimizing rpm, and has the potential to provide good exercise tolerance. 相似文献55.
56.
57.
58.
59.
60.